CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Lever VC

Abhi Kumar, Investment Associate

The Promise Of Alternative Protein In Asia

Abhi Kumar

Abhi Kumar

The recent global coronavirus outbreak, which originated in a wet seafood market, as well as the economic malaise caused by African swine flu over the past year, have begun to expose material financial risks in our protein supply chains and have highlighted the need for us to rethink the way we produce and consume protein. This will be particularly true in Asia, where only 57% of companies have some level of certification from the Global Food Safety Initiative and rapidly rising consumer demand will boost animal protein consumption by nearly 20% over the next eight years, according to OECD-FAO data. In an age of increasing material risks like disease & environmental disasters, it’s likely that animal protein supply chains will find it extremely challenging to adapt to an increasingly volatile global protein market. Therefore, if we are to meet growing consumer demand, there is a crucial need to rethink protein supply chains in Asia and decouple them from crucial material risks like food safety & environmental changes.


At Lever VC, we invest globally in companies that are leveraging decades of research in regenerative medicine and molecular biology to produce real animal protein, free of and with harmful pathogens and drastically lower environmental impacts. One great example is Avant Meats, a Hong Kong-based company cultivating fish meat and other marine proteins to satisfy the growing consumer need for safer, cleaner protein that is relevant to local food culture. The company’s technology platform allows them to grow marine protein products directly from cells, in a production environment that drastically reduces contamination and food safety risks. To showcase their technology, Avant recently produced and publicly taste-tested cultivated fish maw, a food item that is widely revered in Chinese medicine for its health benefits. 


The company will be going public with fish cake and marine protein prototypes later this year. If Avant is successful, its technology could go a long way toward helping meet the market demand of 133 million tonnes of seafood that the OECD & FAO estimates Asia will need by 2028.


Of course, fish and seafood are only one part of the protein sector in Asia. Another significant part of the animal protein industry is milk. With the consumption of nearly 269 million tonnes across Asia in 2019 (OECD-FAO), dairy products made up nearly half the continent’s animal protein consumption in 2019. Here too, technology can help solve supply, food safety, and sustainability challenges. In Singapore, Lever VC portfolio company Turtle Tree Labs is the first company in the world to produce real human and bovine milk directly from mammary cells. Their process is far less susceptible to contamination and the introduction of pathogens than conventional dairy production. TurtleTree’s process is likely to resonate well with consumers who clearly remember the 2008 melamine crisis in China, and who put a priority on food safety when choosing dairy products.


Asia dominates the global protein market, with India and China alone contributing to nearly 50% of the global protein market by 2025. While this creates an urgent need for solutions, there is a growing group of innovative companies in the region developing safer and more sustainable technologies to help meet the protein needs of the Asian consumer. We’re pleased to be able to help fuel their growth as they help to shape the future of protein in Asia.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biotech-startups.lifesciencesreview.com/leadership-perspective/the-promise-of-alternative-protein-in-asia-nwid-417.html